Clinical Trial Search

Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…

Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…

Primary: Disease-free Survival (DFS) — 89.8; 83.8 Percentage of participants who survived — p=0.18

Primary: Percentage of Participants With Immunohistochemical (IHC) Evaluation Between Site A and Others (Sites B, C, D and E) — 16.7; 12.5; 0.0; 8.3 percentage of participants

Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants

Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants

Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants

Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…

Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants

Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF

Primary: Pathologic Complete Response in Breast and Axillary Lymph Nodes. — 16; 14; 21; 5 Participants

Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants

Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants

Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants

Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants

Primary: Pathological Complete Response (pCR) Rate at the Time of Surgery - All Participants — 32.0; 40.0 Percentage of participants — p=0.811

Primary: Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up — 12.9; 7.5 percentage of…

Primary: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). — 23.5; 47.9 percentage of participants with pCR

Primary: Objective Response (OR) — 0; 0; 0; 3 Participants

Primary: Incidence of Treatment-emergent AE's — 16 participants

Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant

Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…

Primary: Description of Age — 49.2 years

Primary: Percentage of Participants With Grade 3 or Greater Diarrhea — 29; 50 percentage of participants

Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) — 3; 3; 15; 15 Participants

Primary: Percentage of Participants With Objective Response as Per Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v. 1.1)…

Primary: Number of Participants With Complete Pathologic Response. — 13 participants

Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…

Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010

Primary: Pathologic Complete Response — 26 percentage of participants